Patents
Literature
Patsnap Copilot is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Patsnap Copilot

276 results about "Pre-condition" patented technology

Pre·con·di·tion. (prē′kən-dĭsh′ən) n. A condition that must exist or be established before something can occur or be considered; a prerequisite. tr.v. pre·con·di·tioned, pre·con·di·tion·ing, pre·con·di·tions. To condition, train, or accustom in advance.

Harmless treatment method for separation and recovery of oily sludge

A harmless treatment technology for separation and recovery of oily sludge comprises the following steps: 1, conveying the oily sludge to a high solid content treatment device, carrying out preliminary screening on large granule impurities in the oily sludge, and conditioning the sludge; 2, conveying pre-conditioned oily sludge to a three-phase centrifuge, and separating oil, water and mud in the oily sludge; 3, conveying the obtained separated liquid to an oil-water separation device, and further carrying out oil and water separation; 4, inputting the obtained oil phase to an oil storage tank, and inputting water to an oily wastewater advanced treatment system; 5, conveying the obtained solid phase sludge transported to a thermal desorption device, and carrying out heating curing separation and condensation oil-water separation in a thermal desorption treatment process; and 6, conveying water output by the oil-water separation device and water output by the thermal desorption device to the oily wastewater advanced treatment system, and carrying out advanced oil-water separation. The method has the advantages of low cost oily sludge treatment cost, convenient maintenance and management, high efficiency and good stability.
Owner:MAIWANG INT BUSINESS SHANGHAI

Methods for providing neuroprotection for the animal central nervous system against the effects of ischemia, neurodegeneration, trauma, and metal poisoning

Methods and pharmaceutical compositions for preconditioning and/or providing neuroprotection to the animal central nervous system against the effects of ischemia, trauma, metal poisoning and neurodegeneration, including the associated cognitive, behavioral and physical impairments. In one embodiment, the method is accomplished by stimulating and stabilizing hypoxia-inducible factor-1α (HIF-1α). HIF-1α is known to provide a neuroprotective benefit under ischemic conditions. Patients at risk for certain diseases or disorders that are associated with risk for cerebral ischemia may benefit, e.g., those at risk for Alzheimer's disease, Parkinson's disease, Wilson's disease or stroke or those patients having head or spinal cord injury. Patients undergoing certain medical procedures that may result in ischemia may also benefit. Initially, the possibility of ischemia or neurodegeneration is recognized. Intranasal therapeutic agents are administered to the upper third of the nasal cavity to bypass the blood-brain barrier and access the central nervous system directly to avoid unwanted and potentially lethal side effects. Therapeutic agents include those substances that interact with iron and/or copper such as iron chelators, copper chelators, and antioxidants. A particular example of such therapeutic agents is the iron chelator deferoxamine (DFO). Intranasal administration of DFO is known to stimulate and/or stabilize HIF-1α and provides an efficient and safe method for pre-conditioning the brain to protect against cerebral ischemia. Moreover, DFO is shown to decrease weight loss in subjects when administered pre and/or post stroke.
Owner:HEALTHPARTNERS RESEACH FOUND

Methods and pharmaceutical compositions for differentially altering gene expression to provide neuroprotection for the animal central nervous system against the effects of ischemia, neurodegeneration, trauma and metal poisoning

ActiveUS20070092500A1Preventing and minimizing and treating neurologic complicationAvoid side effectsOrganic active ingredientsBiocideAntioxidantNose
Methods and pharmaceutical compositions for preconditioning and/or providing neuroprotection to the animal central nervous system against the effects of neurological disorders involving ischemia, trauma, metal poisoning and neurodegeneration, including the associated cognitive, behavioral and physical impairments. In one embodiment, the method is accomplished by stimulating and/or stabilizing hypoxia-inducible factor-1α (HIF-1α). HIF-1α is known to provide a neuroprotective benefit under ischemic conditions. In another embodiment, the method is accomplished by differentially reducing, inhibiting or preventing the increased expression of selected genes caused by neurological disorders. Patients at risk for certain diseases or disorders that are associated with risk for cerebral ischemia may benefit, e.g., those at risk for Alzheimer's disease, Parkinson's disease, Wilson's disease, Huntington's disease, thalassemia or stroke, or those patients having head or spinal cord injury. Patients undergoing certain medical procedures that may result in ischemia may also benefit. Initially, the possibility of ischemia or neurodegeneration is recognized. Intranasal therapeutic agents are administered to the upper third of the nasal cavity to bypass the blood-brain barrier and access the central nervous system directly to avoid unwanted and potentially lethal side effects. Therapeutic agents include those substances that interact with iron and/or copper such as iron chelators, copper chelators, and antioxidants. Particular examples of such therapeutic agents are the iron chelators deferoxamine (DFO) and deferasirox. Intranasal administration of DFO is known to stimulate and/or stabilize HIF-1α and provides an efficient and safe method for pre-conditioning the brain to protect against cerebral ischemia.
Owner:HEALTHPARTNERS RESEACH FOUND
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products